- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02615444
The Effects of Beta-glucan Enriched Oatcake Consumption on Metabolic Disease Risk Factors
An Investigation of the Effects of Consuming Oatcakes Containing 4g of Oat Beta-glucan on Physiological Parameters in Individuals at Risk of Developing Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine whether daily consumption oat beta glucan (4g) for six weeks will have any impact on overweight/obese individuals in terms of risk factors used to define metabolic disease.
Oat beta-glucan has been incorporated into a novel oatcake product manufactured by Nairn's Oatcakes Ltd. Consumption of the oatcake products will deliver enough oat-beta glucan to the diet to meet European Food Safety Authority health claims for lowering blood cholesterol and reducing post-prandial glycaemic responses.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
East Lothain
-
Musselburgh, East Lothain, United Kingdom, EH21 6UU
- Queen Margaret University, Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females 18 years and older
- Waist circumference measurements of ≥94cm for males and 80cm for females, or a body mass index of ≥30kg/m2
- Individuals who are able to provide informed consent
Exclusion Criteria:
- Postmenopausal females
- Smokers
- Individuals who suffer from, or taking medication for, cardiovascular or gastro-intestinal disease
- Impaired glucose tolerance/Diabetes mellitus
- Pregnancy or breastfeeding
- Those who have high dietary fibre intakes (>20g/day)
- Known food allergies to oats, wheat, lactose, or sesame seeds
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Beta-glucan enriched oatcake
Oatcakes which have been enriched with beta-glucan.
Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
|
5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
|
|
Placebo Comparator: Isocaloric control
Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content.
Contains no oat-beta glucan.
Each participant will consume 6.5 Krackawheats daily.
|
6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Waist Circumference
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Blood Pressure
Time Frame: 6 Weeks
|
6 Weeks
|
|
Fasting Serum Triglycerides
Time Frame: 6 weeks
|
6 weeks
|
|
Oral Glucose Tolerance Test
Time Frame: 6 weeks
|
6 weeks
|
|
Fasting Serum HDL Cholesterol
Time Frame: 6 Weeks
|
6 Weeks
|
|
Fasting Serum total Cholesterol
Time Frame: 6 weeks
|
6 weeks
|
|
Interleukin-6
Time Frame: 6 weeks
|
6 weeks
|
|
Energy Intakes (kilocalories) and Macronutrient intakes (grams) from food diaries
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Suzanne Zaremba, Queen Margaret University
Publications and helpful links
General Publications
- Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994 Mar 1;73(7):460-8. doi: 10.1016/0002-9149(94)90676-9.
- Lissner L, Lindroos AK, Sjostrom L. Swedish obese subjects (SOS): an obesity intervention study with a nutritional perspective. Eur J Clin Nutr. 1998 May;52(5):316-22. doi: 10.1038/sj.ejcn.1600567.
- Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev. 2001 May;59(5):129-39. doi: 10.1111/j.1753-4887.2001.tb07001.x.
- Liatis S, Tsapogas P, Chala E, Dimosthenopoulos C, Kyriakopoulos K, Kapantais E, Katsilambros N. The consumption of bread enriched with betaglucan reduces LDL-cholesterol and improves insulin resistance in patients with type 2 diabetes. Diabetes Metab. 2009 Apr;35(2):115-20. doi: 10.1016/j.diabet.2008.09.004. Epub 2009 Feb 20.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QueenMUsz
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.